<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002018</url>
  </required_header>
  <id_info>
    <org_study_id>069B</org_study_id>
    <secondary_id>90-355ME</secondary_id>
    <nct_id>NCT00002018</nct_id>
  </id_info>
  <brief_title>Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects</brief_title>
  <official_title>Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Interferon Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To conduct a double-blind, randomized, dose ranging study of an orally administered low dose&#xD;
      interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-n3</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Didanosine (ddI)&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Seropositivity to HIV-1 by ELISA and Western blot.&#xD;
&#xD;
          -  At least 1 of the HIV-related clinical symptoms or opportunistic infections listed in&#xD;
             protocol.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  If already on zidovudine (AZT) or didanosine (ddI), must have been on this therapy for&#xD;
             at least 75 of the 90 days prior to study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Didanosine (ddI)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Major active opportunistic infection requiring active care within 2 weeks of study&#xD;
             entry.&#xD;
&#xD;
          -  Evidence of chronic hepatitis with severe liver dysfunction:&#xD;
&#xD;
          -  albumin &lt; 2 g/dl and SGOT or SGPT &gt; 5 x upper limit of normal prothrombin time &gt; 1.5 x&#xD;
             upper limit of normal).&#xD;
&#xD;
          -  Other active gastrointestinal, renal, respiratory, endocrine, hematologic,&#xD;
             cardiovascular, neurologic, or psychiatric disorder.&#xD;
&#xD;
          -  Transfusion dependency defined as requiring &gt; 1 unit of packed red blood cells (RBC)&#xD;
             per month within 3 months prior to study entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Experimental medications other than didanosine (ddI).&#xD;
&#xD;
          -  Chronic prophylactic use of any topical or systemic fungal medication such as&#xD;
             ketoconazole, fluconazole, or clotrimazole.&#xD;
&#xD;
          -  Chronic prophylactic use of any topical or systemic anti-viral medication such as&#xD;
             acyclovir or ganciclovir except zidovudine (AZT) or didanosine (ddI).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Asymptomatic at study entry.&#xD;
&#xD;
          -  Presence of antibodies to interferon due to prior therapy.&#xD;
&#xD;
          -  Hospitalization within 2 weeks of study entry.&#xD;
&#xD;
          -  Transfusion dependency.&#xD;
&#xD;
          -  Unwilling or unable to give informed consent.&#xD;
&#xD;
          -  Evidence of any concurrent organ dysfunction listed in Exclusion Co-Existing&#xD;
             Conditions.&#xD;
&#xD;
          -  Unlikely or unable to comply with the requirements of the protocol.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 6 weeks of study entry:&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Excluded within 45 days of study entry:&#xD;
&#xD;
          -  Immunosuppressive agents.&#xD;
&#xD;
          -  Chemotherapy.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Isoprinosine.&#xD;
&#xD;
          -  BCG vaccine.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Hospitalization.&#xD;
&#xD;
        Active intravenous (IV) drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Interferon Type I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

